


At a Glance

ASKA Pharmaceutical Holdings' business operations include a pharmaceutical business, an animal health business, and a testing business. Rather than focusing solely on promoting each business individually, we are using alignment between businesses to drive synergy that will maximize revenue. Here we highlight our initiatives primarily in women's healthcare, a key focus area in the pharmaceutical business, which accounts for approximately 90% of the Group's net sales.



ASKA Pharmaceutical

Net sales **¥56.6 billion**



Ob/Gyn

Leading company

No. 1 domestic market share*

Since achieving the highest sales in the Ob/Gyn field in Japan in the second half of FY2022, we have maintained the leading market share through FY2024. We are promoting a variety of initiatives in addition to the provision of pharmaceuticals, including the dissemination of information on women's health.

* Company estimates

▶ See page 31 for details

Women's Healthcare Research

Over 100 years

Since our founding in 1920, we have used hormonal research to address women's healthcare. We will continue creating a wide variety of drugs in line with the needs of the times so that we can continue contributing to women's health.

▶ See pages 13-14 for details

Share of Thyroid Products Market

95%

The continuous development of our business draws on our 100 years of experience and expertise in the thyroid area. We will strive to ensure quality and stable supply, continuing to contribute to society as a leading company in the thyroid area.

▶ See page 46 for details

R&D Expenses

¥7.0 billion

We are a pharmaceutical company that develops new drugs with a focus on the three priority areas of internal medicine, Ob/Gyn, and urology. We will work with companies in Japan and abroad, accelerating open innovation to provide innovative new drugs.

▶ See pages 57-61 for details

Sales of Uterine Fibroids and Endometriosis Agents

Over ¥10.0 billion

RELUMINA, a uterine fibroids and endometriosis agent, is a growth driver. In FY2024, which marked five years since its 2019 launch, RELUMINA grew into a product with annual sales exceeding ¥10.0 billion.

▶ See page 45 for details

Diversity & Inclusion

13.5%
Ratio of Female Managers

We believe that our ability to achieve sustainable growth and enhance corporate value hinges on respect for diverse values and the exchange of opinions. We aim to reform the workplace environment such that all employees, regardless of gender or other attributes, can play an active role.

▶ See page 74 for details

● Main Products

• Internal Medicine

Hepatic encephalopathy agent RIFXIMA (rifaximin)



Hypothyroidism agent THYRADIN (levothyroxine)



Antihypertensive agent CANDESARTAN "ASKA" (candesartan)



• Ob/Gyn

Uterine fibroids and endometriosis agent RELUMINA (relugolix)



Dysmenorrhea agent DroEthi "ASKA" (drospirenone/ethinylestradiol)



Oral contraceptive Slinda (drospirenone)



• Urology

Endometriosis, uterine fibroids, and prostate cancer agent LEUPRORELIN "ASKA" (leuprorelin)



ASKA Animal Health

Net sales **¥7.2 billion**

● Main Products



Veterinary pharmaceuticals (PA¹) PRID DELTA



Animal feed additives L-isoleucine "ASKA"



Veterinary pharmaceuticals (CA²) TRILOSTANE TABLETS "ASKA"

1. PA: Production animal
2. CA: Companion animal



ASKA Pharma Medical

Net sales **¥0.2 billion**

● Main Products

Nail stress hormone level test kit Cortisol



Hair stress hormone level test kit Cortisol



Hair hormone level measurement kit Dihydrotestosterone



Hair hormone level measurement kit Testosterone



Hormone level measurement kit Proges (Progesterone)

